<DOC>
	<DOCNO>NCT02057796</DOCNO>
	<brief_summary>In country high tuberculosis ( TB ) prevalence , TB invasive bacterial infection lead cause early death patient initiate antiretroviral therapy ( ART ) advance immunodeficiency . We hypothesize systematic 6-month empirical TB treatment initiate 2 week introduction ART HIV-infected adult severe immunosuppression ( CD4 &lt; 100/mm3 ) overt evidence TB reduce risk death invasive bacterial infection . This strategy compare one extensive TB test use point-of-care test ( Xpert MTB/RIF® urine lipoarabinomanan LAM ) chest X-ray identify treat patient least one positive test suggestive TB .</brief_summary>
	<brief_title>Systematic Empirical vs. Test-guided Anti-TB Treatment Impact Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts &lt; 100/mm3</brief_title>
	<detailed_description>Settings : Cambodia , Côte d'Ivoire , Uganda , Vietnam . Design : Multicentre , two-arm , unblinded randomize controlled superiority trial . Objective : To compare 24-week risk death occurrence invasive bacterial infection two experimental strategy HIV-1 infect adult start ART CD4 count &lt; 100/mm3 : ( ) continuous extensive TB screen follow-up time patient present symptom , versus ( ii ) systematic empirical TB treatment start 2 week ART initiation . Trial strategy : At inclusion , participant randomize 1:1 two strategy TB test treatment : extensive TB screening , systematic empirical TB treatment . Extensive TB screening ( arm 1 ) : In arm : - TB screen point-of-care test ( Xpert MTB/RIF® , urine LAM ) chest X-ray use extensively randomisation ( patient ) follow-up ( patient sign symptom suggestive TB ) ; - Only patient meet standardized criterion TB inclusion follow-up receive standard TB treatment ( 2ERHZ/4RH ) ; - ART ( tenofovir ( TDF ) -lamivudine ( 3TC ) /emtricitabine ( FTC ) zidovudine ( AZT ) -lamivudine+ efavirenz ) start immediately randomization patient put TB treatment , 2 week initiation TB treatment others . Systematic empirical TB treatment ( arm 2 ) : In arm : - TB screen point-of-care test use ; - All patient start 6-month standard TB treatment ( 2ERHZ/4RH ) randomization ; ART ( tenofovir-lamivudine/emtricitabine zidovudine-lamivudine+ efavirenz ) start 2 week TB treatment initiation . Both strategy apply first 24 week trial ( intervention period ) . From week-24 week-48 , choice TB test prescription TB treatment leave upon decision investigator trial arm . Inclusion time : 24 month . Follow-up : patient follow 48 week . Statistical analysis : primary analysis intention treat . It compare 24-week probability death invasive bacterial infection arm . Sample size : 1050 participant . This allow demonstration 40 % reduction 24-week probability death invasive bacterial infection arm 2 , compare arm 1 ( α 5 % ; 1-β 80 % ) .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Age ≥18 year ; HIV1 infection document time prior trial entry , per national testing procedure ; CD4 &lt; 100 cells/mm3 ; No history antiretroviral drug use ( except transient ART PMTCT ) ; Able correctly understand trial sign inform consent . HIV2 coinfection ; Contraindication efavirenz ; Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ; Creatinine clearance &lt; 50 ml/min ; Overt evidence TB treatment start immediately ; History TB treatment past 5 year ; Ongoing TB chemoprophylaxis ( isoniazid preventive therapy ) ; Any condition would lead differ ART initiation ( e.g . acute condition require investigation and/or treatment prior ART initiation ) ; Current pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Systematic empiric TB treatment</keyword>
	<keyword>ART</keyword>
	<keyword>TB diagnosis</keyword>
	<keyword>Xpert MTB/RIF®</keyword>
	<keyword>Urine LAM</keyword>
</DOC>